The observed mean PSA concentration at prostate cancer diagnosis in MSH2 carriers was higher than MSH2 non-carriers (19·7 ng/mL vs 5·3 ng/mL); although this difference was not significant (p=0·56). This evidence concerns the gene KLK3 and prostate carcinoma.